Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL557782 | 0.77 | IDO1 (0.43) | IDO1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2650875 | 0.77 | IDO1 (0.42) | IDO1NISCHNPC1RAB9ACASP3 | |
| SCHEMBL558009 | 0.77 | METAP2 (0.46) | METAP2NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL11108412 | 0.77 | CA1 (0.35) | NISCHCYP1A2CYP3A4HPGDLMNA | |
| SCHEMBL558823 | 0.74 | NISCH (0.44) | NISCHNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2651456 | 0.73 | ESR2 (0.40) | NISCHATMTSHR | |
| SCHEMBL4722123 | 0.73 | PDE5A (0.42) | ALDH1A1MAPTHPGDKDM4ETDP1 | |
| SCHEMBL29060392 | 0.72 | IDO1 (0.41) | IDO1METAP2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL557899 | 0.71 | KMT2A (0.41) | IDO1METAP2NISCHNPC1RAB9A | |
| SCHEMBL4721960 | 0.71 | PDE5A (0.49) | SMN1; SMN2CYP1A2CYP2C19ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879004-B2 | Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2018-01-30 | — | — | US | claimed |
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-20150376182-A1 | Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-31 | — | — | US | claimed |
| EP-2953933-A1 | SUBSTITUTED ACETYLENE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | Merck Patent GmbH (DE) | 2015-12-16 | — | — | EP | claimed |
| EP-2271650-B1 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | claimed |
| EP-2563796-B1 | AZA-BICYCLIC AMINE N-OXIDE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND PRO-DRUGS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-18 | — | — | EP | claimed |
| WO-2014121883-A1 | SUBSTITUTED ACETYLENE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR4 | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | WO | claimed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | claimed |
| EP-2688886-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-01-29 | — | — | EP | claimed |
| EP-2493894-B1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-29 | — | — | EP | claimed |
| WO-2011137313-A1 | AZA-BICYCLIC AMINE N-OXIDE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGAND PRO-DRUGS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-03 | — | — | WO | claimed |
| US-20110269787-A1 | Azabicyclic Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-03 | — | — | US | claimed |
| US-20110263605-A1 | Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2011-10-27 | — | — | US | claimed |
| WO-2011056503-A1 | AZABICYCLO[2.2.1] HEPTANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-12 | — | — | WO | claimed |
| WO-2011056573-A1 | AZABICYCLIC COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-05-12 | — | — | WO | claimed |
| EP-2271650-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2011-01-12 | — | — | EP | claimed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | claimed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | claimed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | claimed |
| WO-2009131926-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | IDO1 2159/4885METAP2 3652/4885NISCH 830/4885 |
| US-20110263605-A1 | Azabicyclo[2.2.1]Heptane Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA2, CHRNA5 | IDO1 1125/4885METAP2 4423/4885NISCH 806/4885 |
| US-20150376182-A1 | Substituted Acetylene Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | GRM4, GRIA4, GRIK4 | IDO1 2869/4885METAP2 4246/4885NISCH 4171/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | IDO1 2159/4885METAP2 3652/4885NISCH 830/4885 |
| US-20110269787-A1 | Azabicyclic Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA6, CHRNA5 | IDO1 1999/4885METAP2 4221/4885NISCH 429/4885 |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | IDO1 212/4885METAP2 2796/4885NISCH 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.